Miglitol

Limits on what this shows

• Key negative/null findings: No miglitol-specific study identified in this review showed mitochondrial harm or increased ROS production.
• At-risk subgroups: Not applicable; protective direction.

Regulatory status

Not addressed in the FDA label.

Population evidence

Aoki et al. 2012, Journal of Pharmacological Sciences 120(2):121-128 (in vitro, bEnd.3 microvascular endothelial cells and aortic ring tissue). Miglitol pretreatment at various concentrations suppressed mitochondrial superoxide production and preserved cell viability and DNA integrity under hydrogen peroxide challenge.

Mechanism

Named: effect was associated with activation of AMP-activated protein kinase (AMPK) and phosphorylation of endothelial nitric oxide synthase (eNOS); blocked by the AMPK inhibitor Compound C, supporting a causal AMPK-dependent pathway in this model.

Counter-evidence held on record

Single in vitro study; no human or whole-animal confirmation was identified. Concentrations used in cell culture may not correspond to clinically achievable systemic miglitol exposure, given the drug's local gut action and limited systemic bioavailability at typical doses. Reverse-direction, protective, in vitro finding only. This is not evidence that miglitol should be used for vascular protection, and it is not evidence of mitochondrial harm requiring monitoring.

Limits on what this shows

• Key negative/null findings: No miglitol-specific study identified showing increased oxidative-stress markers.
• At-risk subgroups: Not applicable; protective direction.

Regulatory status

Not addressed in the FDA label.

Population evidence

Aoki et al. 2012, Journal of Pharmacological Sciences 120(2):121-128 (in vitro, drug-specific; same source as the Mitochondrial burden entry above — see Overlap map). Miglitol suppressed oxidative-stress-induced apoptosis and DNA strand breakage in bEnd.3 endothelial cells challenged with hydrogen peroxide.

Mechanism

Same AMPK activation / eNOS phosphorylation pathway described in the Mitochondrial burden entry.

Counter-evidence held on record

This review also located a human RCT reporting that voglibose, a different alpha-glucosidase inhibitor, reduced oxidative-stress markers in obese type 2 diabetic patients, via a WebSearch result snippet; repeated PubMed/Semantic Scholar rate-limiting (429) during this review prevented opening the full source to verify its content, so it is not cited as supporting evidence here and is not used to extend this grade. Voglibose is also chemically distinct from miglitol (a valiolamine derivative versus a deoxynojirimycin derivative), so any class-level inference would be weak even if verified. Reverse-direction, protective, single in vitro study. Not a basis for antioxidant-related consumer claims about miglitol.

Limits on what this shows

• Key negative/null findings: The same label entry states no associated hemoglobin changes accompanied the low serum iron finding, and that the finding did not persist in most affected patients.
• At-risk subgroups: None specifically named in the label. Patients with pre-existing low iron stores are plausibly more likely to cross a lab threshold, but this is not established by drug-specific data.

Regulatory status

Reported in the FDA/DailyMed prescribing information under laboratory test findings.

Population evidence

Pooled clinical trial data cited in the label: low serum iron in 9.2% of miglitol-treated patients versus 4.2% of placebo patients; the label states this "did not persist in the majority of cases."

Mechanism

Not named by the manufacturer. No dedicated mechanistic study of miglitol and iron kinetics was located in this review; a plausible but unconfirmed hypothesis is altered upper-GI transit or luminal chemistry from delayed carbohydrate digestion affecting non-heme iron solubilization.

Counter-evidence held on record

The label's own statement that hemoglobin was unaffected weighs against this being a functionally meaningful iron deficit for most patients; no dedicated interventional study of iron absorption or kinetics on miglitol was identified. This is a bounded, non-persistent, lab-value signal without a hemoglobin correlate. It is not established grounds for routine iron supplementation in miglitol users; any supplementation decision should follow an individually confirmed, persistent lab abnormality.

Limits on what this shows

• Why no grade: The dual condition for ungraded status was met: no Tier B or Tier C evidence exists for miglitol or any alpha-glucosidase inhibitor class member (acarbose, voglibose) regarding copper, and no circulating consumer claim about miglitol and copper was found. Searches were run across PubMed search-listing pages and WebSearch with multiple phrasings ("miglitol copper serum levels" and related terms), and across consumer sources (Drugs.com, GoodRx, Mayo Clinic, Cleveland Clinic, WebMD). These returned no relevant results rather than blocked or error pages, so this reflects a genuine literature gap rather than a tooling failure specific to this category.

Limits on what this shows

• Key negative/null findings: No human study measuring miglitol's effect on gut microbiome composition, with or without a null result, was identified in this review; this is a genuine evidence gap for human compositional data specifically.
• At-risk subgroups: None specifically named; the GI symptom burden documented in the label is dose-related and typically greatest at treatment initiation, diminishing over weeks.

Regulatory status

The FDA label reports flatulence in 41.5% of miglitol patients versus 12.0% on placebo, diarrhea in 28.7% versus 10.0%, and abdominal pain in 11.7% versus 4.7%. These are Tier A but are clinical outcomes correlated with altered colonic carbohydrate load, not direct measurements of microbiome composition (per Hard Rule 2, they are named here as outcomes, not filed as the microbiome finding itself).

Population evidence

Hamada et al. 2020, Metabolism Open (animal, NSY obese diabetic mice, 0.08% dietary miglitol, 4 weeks): increased fecal formic and n-butyric acid, decreased succinic acid, higher total fecal short-chain fatty acids; reduced Prevotella, increased Clostridium cluster XIVa; associated with increased hepatic CYP7A1 (bile-acid synthesis) activity. Zhang et al. 2020, Frontiers in Pharmacology (animal, DBA/1 mice with collagen-induced arthritis): miglitol tested directly and produced an anti-arthritic effect "similar to acarbose but less potent"; the acarbose arm in the same study showed restored bacterial diversity and Firmicutes abundance with enrichment of Oscillospira, Desulfovibrio, and Ruminococcus, but the miglitol arm's own compositional data were not separately detailed in the sections of this article this review could access.

Mechanism

Named: alpha-glucosidase inhibition delivers undigested oligosaccharides and disaccharides to the colon, changing the substrate available for bacterial fermentation and shifting community composition and short-chain fatty acid output.

Counter-evidence held on record

Short-chain fatty acid increases, particularly butyrate, are generally considered favorable in the broader microbiome literature, so labeling this simply as a "risk" oversimplifies a compositional shift whose net effect for humans on miglitol is not established. All compositional and SCFA data located are animal-only (Tier B). This is mechanistic, animal-model evidence for a compositional shift, not an established human microbiome-injury effect. The Tier A clinical correlate (flatulence, diarrhea) is a symptom outcome and should not be conflated with a direct microbiome-composition measurement.

Limits on what this shows

• Key negative/null findings: No whole-body ATP deficit was reported or implied; the mechanism is localized to brown adipose tissue and was framed by the study authors as a beneficial anti-obesity effect.
• At-risk subgroups: Not established; human brown fat mass and activity are much lower than in young mice, so the magnitude of any human effect is uncertain.

Regulatory status

Not addressed in the FDA label.

Population evidence

Sugimoto et al. 2014, Nutrition & Metabolism (Lond) 11:14 (animal, C57BL/6J mice, 0.008% dietary miglitol chosen by the authors to approximate clinical dosing, 8 weeks). Oxygen consumption (VO2) was significantly higher in miglitol-treated obese mice; interscapular brown-fat temperature was 34.7 ± 0.7°C versus 31.5 ± 0.3°C in untreated obese controls; UCP1 mRNA was about 1.5-fold and protein about 1.2-fold higher; PGC1-alpha was also upregulated; body weight was lower despite equal food intake.

Mechanism

Named: beta-3-adrenergic signaling through PKA, HSL, and p38-alpha MAPK upregulates PGC1-alpha and UCP1, which by definition uncouples mitochondrial ATP synthesis from substrate oxidation in brown adipocytes, dissipating chemical energy as heat instead of ATP.

Counter-evidence held on record

Mouse model and mouse dosing; translational magnitude to adult humans, who have comparatively little active brown fat, is uncertain and was not addressed by this study. This is not evidence that miglitol depletes cellular ATP. It describes deliberate, tissue-localized mitochondrial uncoupling in brown fat in an animal model, presented by the study authors as part of a beneficial thermogenic, anti-obesity mechanism, not a systemic energy-production deficit.

Limits on what this shows

• Why no grade: The FDA/DailyMed label states, in the context of its serum-iron finding, that no associated hemoglobin changes accompanied the low serum iron observed in treated patients. This is a Tier A null result, not a positive signal, so it does not itself support a color grade. A targeted PubMed search for acarbose combined with hemoglobin and hematocrit terms returned zero results, and no circulating consumer claim linking miglitol to anemia, hemoglobin, or oxygen-carrying capacity was identified. Tooling note: this review's WebSearch tool-call budget (200 of 200) was exhausted before additional phrasings specific to this category (for example, miglitol combined with erythropoiesis or hematocrit) could be tried via WebSearch, and several PMC full-text pages relevant to broader miglitol physiology returned reCAPTCHA/403 blocks rather than content during this session. A follow-up review is warranted to confirm this gap is genuine literature absence rather than an artifact of this session's access limits.